Purespring Therapeutics

Purespring Therapeutics company information, Employees & Contact Information

Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.

Company Details

Employees
56
Founded
-
Address
2 Royal College Street, The London Bioscience Innovation Centre,united Kingdom
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
London
Looking for a particular Purespring Therapeutics employee's phone or email?

Purespring Therapeutics Questions

News

Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference - GlobeNewswire

Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference GlobeNewswire

Chromatin Bioscience Announces Collaboration with Purespring Therapeutics - PA Media

Chromatin Bioscience Announces Collaboration with Purespring Therapeutics PA Media

Purespring Therapeutics receives UK CTA approval for Phase - GlobeNewswire

Purespring Therapeutics receives UK CTA approval for Phase GlobeNewswire

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN) - GlobeNewswire

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN) GlobeNewswire

Purespring Therapeutics and SwanBio Therapeutics announce licensing agreement for use of FunSel screening platform - Yahoo! Finance UK

Purespring Therapeutics and SwanBio Therapeutics announce licensing agreement for use of FunSel screening platform Yahoo! Finance UK

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases - GlobeNewswire

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases GlobeNewswire

Top Purespring Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant